[{"id":"dc906474-83f8-4b00-bb2c-8553f48dae62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03624543","created_at":"2021-01-18T17:48:24.810Z","updated_at":"2025-02-25T14:07:13.959Z","phase":"Phase 2","brief_title":"CFI-400945 in Patients With Advanced/Metastatic Breast Cancer","source_id_and_acronym":"NCT03624543","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • PGR • PTEN","pipe":" | ","alterations":" PTEN mutation","tags":["HER-2 • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ocifisertib (CFI-400945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-17"},{"id":"262cf44c-be15-41ea-888f-0c8ef3394bfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04176848","created_at":"2021-01-18T20:22:17.239Z","updated_at":"2025-02-25T15:08:55.318Z","phase":"Phase 2","brief_title":"CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT04176848","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • ER • PGR • PLK4","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • ER • PGR • PLK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ocifisertib (CFI-400945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/10/2020","start_date":" 08/10/2020","primary_txt":" Primary completion: 09/15/2022","primary_completion_date":" 09/15/2022","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-08-09"}]